2024-IL-6 억제제를 이용한 AMR 치료 종설 출판
2024-IL 6 KT 종설대한이식학회.pdf
(3.1M)
본문
논문제목: New treatment for antibody-mediated rejection: interleukin-6 inhibitors
제1저자: 박병화
공동 제1저자: 김예나
교신저자: 신호식
초록: Following kidney transplantation, antibody-mediated rejection (AMR) occurs when the antibodies of the immune system attack the transplanted organ, leading to damage of the kidney tissue. De novo human leukocyte antigen donor-specific antibodies (HLADSAs) play a key role in AMR. Current therapeutic approaches include intravenous
immunoglobulin, anti-CD20 antibodies, and plasmapheresis. In cases resistant to
treatment, proteasome inhibitors and C5 inhibitors may be employed. Nevertheless, a
pressing need exists for new medications to improve transplant survival and reduce
complications. In the context of AMR, interleukin (IL)-6 is instrumental in the development and maturation of B cells into plasma cells, which then produce HLA-DSAs targeting the allograft. IL-6 inhibitors are currently under investigation and show promise
due to the essential role of IL-6 in the immune response; however, additional research is
necessary.
